EGFR, PDGFRβ and RAF kinase inhibitory effects of vemurafenib on lysates from cell lines harboring BRAF(V600E) mutations being resistant (patient-3-post) and sensitive (MM200) to vemurafenib, and BRAF wild-type (MelJD).
收藏数据链接：
官方服务：
资源简介：
Highlighted in bold are kinase substrates with P
创建时间：
2015-12-02
